Key Takeaways
- US business hits a milestone, margin focus sharpens: Quarterly revenue reached a $60 million run rate, while gross margin expanded to 57%, putting the stated 60% exit target within reach.
- A one-off dip masks underlying reset: Other regulated markets fell sharply on a B2C-to-B2B model flip, and the institutional business emptied its order book after completing all contracts in H1; both are described as temporary.
- Stelis reaches an inflection point: A first in-house biologic won EU approval, three regulatory inspections were cleared, and a strategic process with a global banker is now underway to find a minority partner.
- The cost base is being structurally reset: A completed $25–30 million OPEX reduction, plus a further US headcount action, underpins a commitment to expand EBITDA margins from 11% toward 15–17% this year.
- What to watch next quarter: Whether the other regulated markets rebound to the promised $40 million run rate, progress on the Stelis strategic review, and receipt of the Arrotex consideration.
US Business: The Margin-First Turnaround
- Run rate milestone: The US business hit a $60 million quarterly run rate, benefiting from seasonality, market share gains on existing products, new launches, and integration of the Chestnut Ridge portfolio.
- Gross margin trajectory: Gross margin reached 57% this quarter, driven by cost reduction, mix improvement, and lower logistics costs. Management believes this level is sustainable and can grow modestly, with a stated goal to exit the financial year at the historical 60% run rate.
- Product strategy is selective: The company exited roughly $25–30 million of products that did not fit the profit model and replaced them with new launches showing good uptake. The focus is on small, niche products where Strides is often the only player or one of two standing, insulating the portfolio from the price erosion seen in larger categories.
- Growth pace is deliberately measured: Management plans fewer than 10 new ANDA filings per year, arguing that relaunching existing products involves nearly as much work as developing new ones. About 20 launches per year would be ideal, with 80–100 unlaunched or relaunched products in the pipeline expected to meet the ~60% gross margin and 22–23% EBITDA criteria.
- Full-year revenue framing: The exit run rate target is $240–250 million, but absolute full-year revenue may land $10–15 million below $250 million. Management argues the same profit outcome is achievable at either level because of the gross margin focus, and the H2 average quarterly run rate of $65–67 million is not considered difficult to manage.
Arun Kumar: "We will not be in any urgency to grow the US business at a pace that we won't be able to manage and retain our profit strategy."
Other Regulated Markets & Institutional Business: Temporary Dips
- Other regulated markets: Revenue declined significantly, a roughly Rs. 60–70 crore reduction, because of a decision to move from a B2C to a B2B model, particularly in Germany. Management described this as an accounting flip and a one-off, and expects a return to the $40 million quarterly run rate as early as the current quarter, with improved gross margins from the new model.
- Institutional business: Performance was muted because all prior contractual obligations were completed in H1, leaving the order book at zero. New contracts have not yet been awarded and are not expected until Q4, so significant softness will persist in the near term. Production is being shifted to Kenyan operations under a "Made in Africa, for Africa" strategy.
Stelis: Regulatory Progress, Strategic Review, and the Path to Breakeven
- Regulatory milestones: Stelis completed three significant regulatory inspections (two FDA, one European authority), received an EIR for the first FDA audit, and is already EU-approved. On the Friday before the call, it received its first in-house developed biologic product approval for the European market.
- CDMO customer build: Three new customers were onboarded during the quarter, though reported numbers remain weak because the revenue recognition model is purely based on work done. Onboarding a customer from award to actual contract takes 8–9 months.
- Strategic process launched: A global banker has been appointed for a strategic review to find a minority strategic partner for Stelis. All strategic options are on the table, and management targets March 2023 for a more concrete update.
- Debt reduction pathway: Promoters, along with TPG, are committed to infuse an additional Rs. 500 crores to meet obligations, which would reduce Stelis debt from Rs. 1,100 crores to Rs. 600 crores. A successful second capital raise via the strategic process could make Stelis debt-free. Management stated all solutions to meet debt obligations will be achieved without recourse to Strides.
- Breakeven timeline: The biopharma business has a 7–9 year gestation period and is about five years in; management expects roughly 18 more months to reach cash breakeven.
- Product vs. CDMO separation: When asked whether separating the products business under Biolexis weakens the valuation case or pushes back breakeven, management argued it does not, because a CDMO and a product company cannot coexist due to conflict of interest. The specific valuation and breakeven timing impact was not directly addressed.
Arun Kumar: "No, it doesn't, because you can't be a CDMO and a product company at the same time. It is a conflict of interest."
Margins, Costs & the Balance Sheet
- Gross margin expansion: Gross margin reached 57%, up significantly, and management believes this level is sustainable with room for modest growth. The improvement came from cost reduction, mix, and lower logistics costs.
- OPEX reduction underway: A $25–30 million OPEX reduction has been completed, with the last big action being a warn notice to reduce US headcount, yielding a further $11 million reduction. Fixed costs including employee costs and other expenses are well controlled at a Rs. 420–425 crore quarterly run rate, and a further exercise targets at least Rs. 150 crores in additional OPEX reduction, though the flow-through will be visible only next year due to notice periods and severance costs.
- EBITDA margin commitment: Management expressed confidence in expanding margins from 11% to 15–17% within this financial year, and reiterated that the previously indicated 21–22% EBITDA margin by FY24 remains achievable if the disciplined approach continues for the next 2–3 quarters.
- Debt elevation explained: Net debt increased from Rs. 1,350 crores (FY22) to over Rs. 2,000 crores. Of the ~Rs. 200 crore increase, Rs. 145 crores was due to exchange rate fluctuations. Management noted that Rs. 700 crores of the FY22 figure was equity investment in Stelis, but a requested breakup of the Rs. 650 crore-plus increase was not provided on the call and was deferred offline.
- Working capital and deleveraging: A significant inventory pickup for US and UK operations occurred as business returned to normalcy, and reducing those inventory levels is expected to improve cash flows in H2. Management is very confident of meeting the guided debt reduction of Rs. 1,000 crores, with most occurring in H2, and expects exit net debt to EBITDA below 3x based on Q4 EBITDA annualized at more than Rs. 150 crores.
Portfolio Catalysts & Other Updates
- Kauliv (recombinant PTH): Received EMA market authorization, making Strides only the second recombinant player in the market. National approvals in each European country are still required and may take 5–6 months, with a good uptake in numbers expected from H2 onward. Management declined to provide product-specific sales targets, stating only that it is a high gross margin, high EBITDA product.
- AmbiVax: All clinical data was submitted to Indian authorities, but because it is no longer an emergency, authorities have asked for additional clinical work. Discussions with Boston partners are ongoing, and the additional work may take 2–3 months before resubmission. The vaccine is positioned as the world's only thermostable vaccine, designed for frontier markets where cold chain is a challenge, and the company is working with global NGOs and large governments for partnerships.
- Arrotex consideration: The $94 million payment is due by December 31, and management is working to bring forward receipt. Necessary paperwork and Board resolutions on the Arrotex side are very close to completion. Apotex, co-owner of Arrotex, announced the sale of its business to SK Capital a couple of weeks prior.
- Kenya deconsolidation: The Kenya business has been deconsolidated from Strides, with the company now owning 49% effective this quarter. The topline is no longer consolidated, but the economics will be.
Arun Kumar: "I can reassure the investors that there are no contingencies surrounding this payment..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US gross margin exit run rate | Exit FY23 at 60% GM run rate | FY23 exit |
| US revenue exit run rate | $240–250 million exit run rate | FY23 exit |
| Other regulated markets recovery | Return to $40 million quarterly run rate | Q3 FY23 (current quarter) |
| EBITDA margin expansion | Expand from 11% to 15–17% | Within FY23 |
| EBITDA margin target | 21–22% EBITDA margin | FY24 (if discipline continues for 2–3 quarters) |
| OPEX reduction | At least Rs. 150 crores reduction over current levels | Flow-through visible next year |
| Net debt reduction | Rs. 1,000 crores reduction, most in H2 | FY23 |
| Exit net debt to EBITDA | Below 3x, based on Q4 EBITDA annualized (>Rs. 150 crores) | FY23 exit |
| Stelis debt reduction | Rs. 500 crores infusion reduces debt to Rs. 600 crores | Before end of FY23 |
| Stelis cash breakeven | Biopharma business reaches cash breakeven | ~18 months |
| Stelis strategic update | Concrete update on strategic process | March 2023 |
| Arrotex consideration | $94 million receipt | December 31 (working to bring forward) |
| Kauliv national approvals | National registrations across European countries | 5–6 months |
| AmbiVax resubmission | Additional clinical work completed and resubmitted | 2–3 months |
| Institutional business recovery | New contracts awarded and business resumes | Q4 FY23 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| US business quarterly run rate | $60 million, benefiting from seasonality, new launches, and Chestnut Ridge integration |
| US business gross margin | 57%, driven by cost reduction, improved product mix, and lower logistics costs |
| US business gross margin target (exit FY23) | 60%, historical run rate |
| US business full-year revenue guidance | $250 million, exit run rate of $240–$250 million; absolute may be $10–$15 million less |
| US business H1 revenue | $106 million |
| Other regulated markets revenue impact | ₹60–70 crore reduction, one-off due to shift from B2C to B2B model, especially in Germany |
| Other regulated markets historical quarterly run rate | ~$40 million, expected to return to this level as early as Q3 |
| Institutional business H1 revenue | $39 million, with 0 order book currently as new contracts not yet awarded |
| Consolidated gross margin | 57%, sustainable and expected to grow modestly |
| EBITDA margin | 11%, double-digit after 4–5 quarters; expansion to 15–17% expected within FY23 |
| EBITDA margin target (previously indicated) | 21–22% by FY24 |
| Interest cost | ₹46.6 crore, similar to last quarter on a net basis |
| Net debt increase | ~₹200 crore, of which ₹145 crore from exchange rate movement between 1 Apr and 30 Sep |
| Net debt (current) | Over ₹2,000 crore, up from ₹1,350 crore in FY22; ₹700 crore of FY22 figure was equity investment in Stelis |
| OPEX reduction completed | $25–30 million, with further $11 million reduction from US headcount actions expected |
| OPEX reduction target (annualized) | At least ₹150 crore over current level, flow-through visible next year |
| Stelis additional capital infusion | ₹500 crore committed by promoters and TPG |
| Stelis debt reduction (group level) | ₹1,300–1,500 crore between Strides and Stelis |
| Stelis current debt | ₹1,100 crore, expected to reduce to ₹600 crore after infusion |
| Stelis breakeven timeline | 18 months |
| Arrotex consideration (first part) | $94 million, due by 31 Dec contractual date |
| Arrotex consideration (second part) | $12 million, subject to certain conditions |
| PTH (Kauliv) global market opportunity | $800 million, Europe ~$200 million; 20+ customers signed |
| New CDMO customers onboarded (Stelis) | 3 during the quarter |
| US portfolio approved products | ~260 approved; 65 Endo products launched; 20+ pending approval |
| Additional viable products in unlaunched/relaunched portfolio | 80–100 products expected to meet ~60% GM and 22–23% EBITDA criteria |
| Products with BE studies available | Over 300 |
| Target new launches per year | ~20 |
| US portfolio guided revenue range | $400–500 million |
| Average revenue per small/niche product | $3–5 million |
| Products exited that did not fit model | $25–30 million of products removed |
| Guided debt reduction | ₹1,000 crore, most in H2 |
| Exit net debt to EBITDA target | Less than 3x |
| Q4 EBITDA expected | More than ₹150 crore |